

**Amendments to the Claims**

Please cancel claims 1 and 5 without prejudice or disclaimer.

Pursuant to 37 C.F.R. §1.121(c), this listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

1. (Cancelled)
2. (Original) A diagnostic method of predicting susceptibility to PD, based on the detection of the "PD-susceptibility haplotype", as herein defined, in an individual.
3. (Original) A method of screening for a genetic predisposition to PD, wherein said method involves the steps of:
  - (a) providing a blood sample from an individual to be screened;
  - (b) analyzing the DNA from the blood sample of (a) for the presence or absence of the "PD-susceptibility haplotype", as herein defined, by appropriate means;wherein the presence of the "PD-susceptibility haplotype" indicated a higher predisposition to PD, and the absence of the "PD-susceptibility haplotype" indicated a lower predisposition to PD, compared to a control.
4. (Original) A method of testing a blood sample of a human subject for the presence of the "PD-susceptibility haplotype", by analyzing the DNA of said blood sample by appropriate means, wherein the presence of the "PD-susceptibility haplotype" indicated a higher predisposition of said human subject to PD, and the

Applicants: Hermona Soreq, et al.  
U.S. Serial No. Not Yet Known  
Filed: Herewith  
Page 5

absence of the "PD-susceptibility haplotype" indicated a lower predisposition of said human subject to PD, compared to a control.

5. (Cancelled)